A mix-up involving blood pressure medication has led to a Canada-wide recall after it was discovered that some bottles contained the incorrect drug.
A recall has been issued for two lots of MAR-Amlodipine 5-milligram tablets, which are prescribed for high blood pressure, Health Canada said in a Feb. 9 advisory.
The Type 1 recall was initiated because there is a chance that manufacturer Marcan Pharmaceuticals Inc. may have unintentionally put medication meant for the treatment of low blood pressure in some MAR-Amlodipine bottles, the alert said.
A Type 1 recall implies a significant chance that the use of a recalled item could cause serious health complications or death, the health agency said.
Medication users can determine if they have the right medication by inspecting the pills. The proper MAR-Amlodipine tablets feature eight sides, are white to off-white in colour, and display the numbers “210” and “5” on their surface, the advisory said.
The medication for low blood pressure, midodrine, comes in the form of 2.5-milligram tablets that are white and round, featuring the inscription ‘M2’ on one side and a dividing line on the opposite side.
Health Canada is warning that individuals with high blood pressure who inadvertently use midodrine could experience severe side effects, including elevated blood pressure, dizziness, fainting, and potentially organ damage.
“If your bottle contains any unusual tablets or if you are unsure, return it to your pharmacy,” Health Canada said. “If you are unable to get a replacement immediately, continue taking your medication as directed but do not take the round tablets.”
Anyone who feels dizzy, has abnormally high blood pressure, or is experiencing a slow heartbeat should contact a healthcare professional or dial 911, Health Canada said.
Those experiencing chest pain, a sudden headache, impaired speech, or a loss of movement or sensation in any part of their body should seek urgent medical assistance, the advisory said.
Health Canada said it is monitoring the company’s recall and investigation, including the execution of corrective measures to prevent the issue from reoccurring, and noted that it will notify the public should any new health risks be discovered.
The agency said all health product-related side effects or complaints should be referred to Health Canada.
